Zydus Lifesciences Performance dei guadagni passati

Il passato criteri di controllo 5/6

Zydus Lifesciences ha registrato una crescita degli utili a un tasso medio annuo di 19%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 13.6%. I ricavi sono stati in crescita a un tasso medio annuo di 7.5%. Il ritorno sul capitale proprio di Zydus Lifesciences è 19.4% e ha margini netti di 20.2%.

Informazioni chiave

19.0%

Tasso di crescita degli utili

19.3%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	17.5%
Tasso di crescita dei ricavi	7.5%
Rendimento del capitale proprio	19.4%
Margine netto	20.2%
Prossimo aggiornamento sui guadagni	12 Nov 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

Ripartizione dei ricavi e delle spese

Come Zydus Lifesciences guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NSEI:ZYDUSLIFE Ricavi, spese e utili (INR Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Jun 24	206,153	41,685	43,988
31 Mar 24	195,474	38,365	42,457
31 Dec 23	190,241	29,562	40,238
30 Sep 23	187,760	28,109	38,955
30 Jun 23	184,127	25,262	38,143
31 Mar 23	172,374	19,649	37,649
31 Dec 22	164,335	20,785	34,572
30 Sep 22	157,110	19,629	33,594
30 Jun 22	153,361	21,710	33,072
31 Mar 22	151,099	22,416	32,498
31 Dec 21	157,609	23,267	33,869
30 Sep 21	157,389	23,269	34,155
30 Jun 21	156,130	22,600	33,716
31 Mar 21	144,035	22,016	31,250
31 Dec 20	150,076	18,465	33,882
30 Sep 20	148,501	16,932	33,738
30 Jun 20	143,967	13,270	33,550
31 Mar 20	142,531	11,766	33,080
31 Dec 19	142,338	12,448	30,652
30 Sep 19	141,736	13,816	29,702
30 Jun 19	137,682	16,919	28,947
31 Mar 19	131,656	18,488	28,315
31 Dec 18	126,706	19,954	26,962
30 Sep 18	123,526	20,305	26,377
30 Jun 18	126,133	21,168	25,801
31 Mar 18	119,049	17,946	24,874
31 Dec 17	111,691	15,705	23,076
30 Sep 17	102,206	13,511	22,178
30 Jun 17	93,397	12,277	15,718
31 Mar 17	93,765	14,904	20,774
31 Dec 16	97,494	11,323	22,840
30 Sep 16	97,971	12,812	22,110
30 Jun 16	97,221	14,186	13,863
31 Mar 16	94,268	19,339	19,875
31 Dec 15	95,901	14,843	26,749
30 Sep 15	92,453	13,766	26,744
30 Jun 15	89,795	12,638	26,277
31 Mar 15	86,513	11,506	19,060
31 Dec 14	82,955	10,394	24,740
30 Sep 14	79,777	9,435	24,184
30 Jun 14	76,165	8,488	24,041
31 Mar 14	72,034	8,036	23,771
31 Dec 13	68,204	8,266	21,595

Guadagni di qualità: ZYDUSLIFE ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di ZYDUSLIFE (20.2%) ZYDUSLIFE sono più alti rispetto allo scorso anno (13.7%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di ZYDUSLIFE sono cresciuti del 19% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di ZYDUSLIFE nell'ultimo anno ( 65% ) supera la media quinquennale ( 19% all'anno).

Guadagni vs Settore: La crescita degli utili ZYDUSLIFE nell'ultimo anno ( 65% ) ha superato la percentuale del settore Pharmaceuticals 19.1%.

Zydus Lifesciences Performance dei guadagni passati

Il passato criteri di controllo 5/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv

Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg

Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease

Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets

Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00